Melbourne, Australia, 6 January 2016 : Adherium Limited (ASX: ADR), a global leader in digital health technologies which address sub-optimal medication use in chronic disease, will present a corporate overview at the EBD Biotech Showcase Conference, taking place in San Francisco between 11-13 January 2016.
San Francisco in January each year sees the largest global gathering of life sciences and healthcare investors and analysts, together with company executives across a number of parallel conferences and private meetings.
Adherium’s company presentation during which it will provide an overview of 2015 and future directions for the Company will take place in Room Mission II at 9.00 a.m. on Monday 11 January. Further information, please see http://www.ebdgroup.com/bts/index.php
Adherium (ASX:ADR) is an Australian Securities Exchange listed company which develops, manufactures and supplies digital health technologies which address sub-optimal medication use and improve health outcomes in chronic disease.
Adherium is a provider of digital health solutions to pharmaceutical, remote patient monitoring and clinical trials companies and organisations. The Company’s proprietary Smartinhaler™ platform has been independently proven to improve medication adherence and health outcomes for patients with chronic respiratory disease. Adherium has the broadest range of "smart" medication sensors for respiratory medications globally.
Clinical outcomes data has proven that the Smartinhaler platform can improve adherence by up to 59% in adults and 180% in children and reduce severe episodes by 60% in adults. In addition, interim data from a study at the University of Sheffield demonstrated a 144% increase in adherence, a restoration of lung function to 100% and a 37% reduction in oral steroids indicating reduced severe exacerbations in children. Both children and adults benefit from improved quality-of-life as a result of their improved adherence, demonstrating a substantial gain over current best practice treatment.
The Smartinhaler™ platform has so far been used in 63 projects (clinical, device validation or other) and has been referenced in 33 peer reviewed journal articles. The Company has received FDA 510(k) notifications for clearance to market and CE Marks for its devices and software, which allows it to sell these devices into international markets.
Issued for and on behalf of Adherium by Instinctif Partners.
For more information please contact: email@example.com